TScan Therapeutics Inc. (TCRX)
TScan Therapeutics Statistics
Share Statistics
TScan Therapeutics has 56.59M shares outstanding. The number of shares has increased by 7.05% in one year.
| Shares Outstanding | 56.59M |
| Shares Change (YoY) | 7.05% |
| Shares Change (QoQ) | 6.03% |
| Owned by Institutions (%) | 34.99% |
| Shares Floating | 46.81M |
| Failed to Deliver (FTD) Shares | 10.92K |
| FTD / Avg. Volume | 2.75% |
Short Selling Information
The latest short interest is 2M, so 3.74% of the outstanding shares have been sold short.
| Short Interest | 2M |
| Short % of Shares Out | 3.74% |
| Short % of Float | 4.22% |
| Short Ratio (days to cover) | 3.56 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -2.06. TScan Therapeutics's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -2.06 |
| PS Ratio | 120.9 |
| Forward PS | 0.5 |
| PB Ratio | 1.41 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
TScan Therapeutics Inc. has an Enterprise Value (EV) of 474.88M.
| EV / Earnings | -3.72 |
| EV / Sales | 168.64 |
| EV / EBITDA | -3.97 |
| EV / EBIT | -3.52 |
| EV / FCF | -4.14 |
Financial Position
The company has a current ratio of 8.14, with a Debt / Equity ratio of undefined.
| Current Ratio | 8.14 |
| Quick Ratio | 8.14 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | - |
| Cash Flow / Debt | null |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is -44.02%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | -44.02% |
| Revenue Per Employee | $14,515.46 |
| Profits Per Employee | $-657,211.34 |
| Employee Count | 194 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -82.36% in the last 52 weeks. The beta is 0.91, so TScan Therapeutics's price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | -82.36% |
| 50-Day Moving Average | 2.01 |
| 200-Day Moving Average | 4.42 |
| Relative Strength Index (RSI) | 27.78 |
| Average Volume (20 Days) | 396.52K |
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 2.82M and earned -127.5M in profits. Earnings per share was -1.14.
| Revenue | 2.82M |
| Gross Profit | 2.82M |
| Operating Income | -134.82M |
| Net Income | -127.5M |
| EBITDA | -119.74M |
| EBIT | -134.82M |
| Earnings Per Share (EPS) | -1.14 |
Balance Sheet
The company has 178.69M in cash and 65.31M in debt, giving a net cash position of 113.38M.
| Cash & Cash Equivalents | 178.69M |
| Total Debt | 65.31M |
| Net Cash | 113.38M |
| Retained Earnings | -375.1M |
| Total Assets | 371.12M |
| Working Capital | 256.77M |
Cash Flow
In the last 12 months, operating cash flow was -110.82M and capital expenditures -3.83M, giving a free cash flow of -114.65M.
| Operating Cash Flow | -110.82M |
| Capital Expenditures | -3.83M |
| Free Cash Flow | -114.65M |
| FCF Per Share | -1.02 |
Margins
Gross margin is 100%, with operating and profit margins of -4.79K% and -4.53K%.
| Gross Margin | 100% |
| Operating Margin | -4.79K% |
| Pretax Margin | -4.53K% |
| Profit Margin | -4.53K% |
| EBITDA Margin | -4.25K% |
| EBIT Margin | -4.79K% |
| FCF Margin | -4.07K% |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -89.76% |
| FCF Yield | -159.52% |
Analyst Forecast
The average price target for TCRX is $10, which is 687.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 687.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -1.3 |
| Piotroski F-Score | 3 |